| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Kaupinen Wes | 15% | $38,555,729 | 1,644,869 | Kaupinen Wes | 13 Dec 2024 | |||
| BIOTECHNOLOGY VALUE FUND L P | 10% | $74,049,052 | 1,181,194 | BVF PARTNERS L P/IL | 30 Sep 2025 | |||
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.4% | -13% | $51,556,256 | +$6,766,571 | 822,400 | +15% | SUVRETTA CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| Frazier Life Sciences Public Fund, L.P. | 6% | +22% | $70,982,116 | +$16,164,419 | 706,360 | +29% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| Samsara BioCapital, L.P. | 3.1% | -50% | $8,989,600 | -$8,989,600 | 339,743 | -50% | Samsara BioCapital, L.P. | 30 Jun 2025 |
| Dellora Investments LP | 1.3% | $3,306,892 | 141,079 | Dellora Investments LP | 13 Dec 2024 |
As of 31 Dec 2025, 94 institutional investors reported holding 4,609,067 shares of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PVLA). This represents 39% of the company’s total 11,772,667 outstanding shares.
The largest institutional shareholders of PALVELLA THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PVLA) together control 37% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6.1% | 722,400 | 0% | 2% | $75,613,608 |
| VANGUARD GROUP INC | 4.8% | 560,616 | +13% | 0% | $58,679,676 |
| BlackRock, Inc. | 4.7% | 559,065 | +15% | 0% | $58,517,334 |
| STATE STREET CORP | 3.6% | 420,462 | +206% | 0% | $44,009,758 |
| JENNISON ASSOCIATES LLC | 3.3% | 387,483 | +262% | 0.02% | $40,557,846 |
| FEDERATED HERMES, INC. | 3.1% | 368,038 | +8.6% | 0.06% | $38,522,537 |
| MORGAN STANLEY | 1.9% | 220,662 | +59% | 0% | $23,096,692 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 178,992 | +6.5% | 0% | $18,739,109 |
| EVENTIDE ASSET MANAGEMENT, LLC | 0.86% | 101,748 | 0.17% | $10,649,963 | |
| GOLDMAN SACHS GROUP INC | 0.84% | 98,935 | -58% | 0% | $10,355,526 |
| Clio Asset Management LLC | 0.78% | 91,642 | +0% | 7.4% | $9,592,168 |
| NEXTBio Capital Management LP | 0.7% | 82,686 | 0% | 5.1% | $8,654,744 |
| Siren, L.L.C. | 0.64% | 75,000 | 0.23% | $7,850,250 | |
| AWM Investment Company, Inc. | 0.59% | 69,416 | 0% | 0.7% | $7,265,773 |
| Clearbridge Investments, LLC | 0.51% | 60,628 | 0.01% | $6,345,881 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.41% | 47,681 | 0% | $4,990,771 | |
| NEUBERGER BERMAN GROUP LLC | 0.38% | 44,901 | 0% | $4,699,787 | |
| Lisanti Capital Growth, LLC | 0.35% | 41,470 | 1% | $4,340,665 | |
| Blue Owl Capital Holdings LP | 0.34% | 40,259 | -58% | 0.32% | $4,213,910 |
| UBS Group AG | 0.31% | 36,505 | +79% | 0% | $3,820,979 |
| ROYCE & ASSOCIATES LP | 0.25% | 30,010 | -39% | 0.03% | $3,141,147 |
| BARCLAYS PLC | 0.21% | 25,136 | +157% | 0% | $2,630,986 |
| RENAISSANCE TECHNOLOGIES LLC | 0.19% | 22,530 | -75% | 0% | $2,358,215 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 21,633 | +3% | 0% | $2,264,326 |
| Nuveen, LLC | 0.17% | 19,576 | +54% | 0% | $2,049,020 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 4,609,067 | $482,433,725 | +$93,113,354 | $104.67 | 94 |
| 2025 Q3 | 8,525,488 | $534,466,075 | +$183,107,977 | $62.69 | 100 |
| 2025 Q2 | 5,909,706 | $133,205,244 | +$16,635,084 | $22.54 | 64 |
| 2025 Q1 | 5,123,397 | $143,404,590 | +$33,701,617 | $27.99 | 40 |
| 2024 Q4 | 4,033,052 | $48,417,227 | +$48,417,227 | $12.00 | 32 |